lundi 28 septembre 2015

Onco Actu du 28 septembre 2015

1. Biologie

MD Anderson study identifies leukemia tumor suppressor [MD Anderson Cancer Center]

Stopping cancer’s scrum for survival [Cancer Research UK]

3.1 Tabac

Expert opinion – Constant craving: how can science help smokers to quit? [Cancer Research UK]

Rare 'healthy' smokers' lungs explained [BBC News]

Video games with smoking characters lack tobacco warnings [Reuters]

4. Dépistage, diagnostic et pronostic

Roche launches the cobas EGFR Mutation Test v2 for use with either plasma or tumour tissue samples [Roche]

4.12 Biopsies liquides

FDA Warns Liquid Biopsy Maker [The Scientist]

5. Traitements

Experimental drug combination shrinks lab-grown pancreatic tumours [Cancer Research UK]

5.2 Pharma

Running Novartis [In the Pipeline]

Cometriq plays wallflower as Opdivo’s dance card fills [EP Vantage]

Bristol-Myers Squibb Announces U.S. Food and Drug Administration Regulatory Filing Update for the Opdivo+Yervoy Regimen in Patients with Previously Untreated Advanced Melanoma [BMS]

5.2.1 Pharma - Partenariats

Bristol-Myers Squibb and Moffitt Cancer Center Enter Into a Collaboration Agreement as Part of U.S. Immuno-Oncology Rare Population Malignancy Program [BMS]

5.3.4 Traitements - AMM (FDA, EMA)

Amgen's leukemia drug gets conditional European approval [Reuters]

Roche skin cancer combination therapy gets EU panel backing [Reuters]

Janssen’s daratumumab accepted for accelerated CHMP assessment for treatment of European patients with heavily pre-treated multiple myeloma [Johnson & Johnson]

Merck and Pfizer Announce FDA Orphan Drug Designation for Investigational Immunotherapy Avelumab in Merkel Cell Carcinoma [Pfizer]

Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 21-24 September 2015 [EMA]

CHMP recommends EU approval for Roche’s combination of Cotellic (cobimetinib) and Zelboraf (vemurafenib) in advanced melanoma [Roche]

New treatment option for patients with rare blood cancer [EMA]

5.4 Traitements - Economie

Peter Bach on drug pricing: “A system so broken even a child could manipulate it” [Scope Blog]

Martin Shkreli Is Just a Tiny Part of a Huge Problem [The Nation]

5.6.11 ESMO- Rein

In A First, Kidney Cancer Drug Extends Survival [Forbes]

5.6.13 ESMO - Prostate

OncoGenex Presents Additional Phase 3 SYNERGY Analyses Showing Custirsen Significantly Reduced Serum Clusterin Levels in Metastatic Prostate Cancer Patients; Low Levels Correlate with Improved Survival in Those at Increased Risk for Poor Outcomes [OncoGenex]

5.6.4 ESMO - Poumon

Opdivo (nivolumab) Demonstrates Long Term Survival Benefit in Patients with Previously Treated Non-Squamous Non-Small Cell Lung Cancer in CheckMate -057 [BMS]

6. Lutte contre les cancers

Understanding why some men still die from testicular cancer [The Institute of Cancer Research]

NHS Strategy for Personalised Medicine revealed [PHG Foundation]

A case of me: clinical cancer sequencing and the future of precision medicine [Cold Spring Harbor]

NHS Strategy for Personalised Medicine revealed [PHG Foundation]

6.1 Observation

Breast cancer survival data shows age discrimination, experts warn [The Telegraph]

UK cancer survival improves but continues to lag behind best in Europe [Cancer Research UK]

UK cancer survival worst in western Europe [The Telegraph]

6.5 Médecines alternatives

Cancer quackery, Republican presidential candidates, and political influence [Respectful Insolence]

6.8 Communication

Why Everything Is Bad for You [NY Times]